safety of cell therapy with mesenchymal stromal cells (safecell) a systematic review and meta-analysis of clinical trials细胞疗法的安全性与间充质基质细胞(safecell)临床试验的系统回顾和荟萃分析.pdfVIP

Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials 1,5 2,5 5 5 6 Manoj M. Lalu , Lauralyn McIntyre *, Christina Pugliese , Dean Fergusson , Brent W. Winston , 7 8 3,4 John C. Marshall , John Granton , Duncan J. Stewart , for the Canadian Critical Care Trials Group 1 Department of Anesthesiology, University of Ottawa, Ottawa, Canada, 2 Department of Medicine (Division of Critical Care), University of Ottawa, Ottawa, Canada, 3 Regenerative Medicine Program, The Ottawa Hospital Research Institute, Ottawa, Canada, 4 Department of Cell and Molecular Medicine, University of Ottawa, Ottawa, Canada, 5 The Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Canada, 6 Department of Critical Care Medicine, University of Calgary, Calgary, Canada, 7 Department of Surgery (Critical Care), University of Toronto, Toronto, Canada, 8 Department of Medicine (Critical Care), University of Toronto, Toronto, Canada Abstract Background: Mesenchymal stromal cells (MSCs, ‘‘adult stem cells’’) have been widely used experimentally in a variety of clinical contexts. There is interest in using these cells in critical illness, however, the safety profile of these cells is not well known. We thus conducted a systematic review of clinical trials that examined the use MSCs to evaluate their safety. Methods and Findings: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (to June 2011), were searched. Prospective clinical trials that used intravascular delivery of MSCs (intravenously